CytRx begins Phase II pancreatic ductual adenocarcinomas trial

The open-label Phase II clinical trial will evaluate the preliminary efficacy and safety of INNO-206 in pancreatic cancer.

The patients enrolled in the trial will be treated with intravenously administered INNO-206 once every three weeks for up to eight cycles at a dose of 350mg/m2 and will be evaluated for objective tumor response.

CytRx president and CEO Steven Kriegsman said, "We are delighted to initiate a Phase 2 trial with INNO-206 in this solid tumor indication and are highly encouraged by prior animal trial results in pancreatic cancer models, which are extremely difficult to treat."

The secondary endpoints include disease control (complete and partial responses, and stable disease at four months), as well as progression-free and overall survival.